Literature DB >> 19352111

Light chains: heavy burden in kidney transplantation.

Eliot C Heher1, Thomas R Spitzer, Nelson B Goes.   

Abstract

Plasma cell dyscrasias are frequently encountered malignancies which are often associated with kidney disease through the production of monoclonal immunoglobulin (Ig). Recent advances in the field include the availability of an assay for free light chains, the introduction of new agents which more effectively target malignant plasma cells, and refinements in the application of stem-cell transplantation. Well-selected patients with plasma cell dyscrasias whose monoclonal Ig is well controlled may be candidates for kidney transplantation. Kidney transplant patients with allograft dysfunction from recurrent or de novo monoclonal Ig deposition can be successfully identified and treated with these new approaches.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19352111     DOI: 10.1097/TP.0b013e31819b9977

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  5 in total

Review 1.  Kidney disease associated with plasma cell dyscrasias.

Authors:  Eliot C Heher; Nelson B Goes; Thomas R Spitzer; Noopur S Raje; Benjamin D Humphreys; Kenneth C Anderson; Paul G Richardson
Journal:  Blood       Date:  2010-05-12       Impact factor: 22.113

Review 2.  Kidney disease and multiple myeloma.

Authors:  Eliot C Heher; Helmut G Rennke; Jacob P Laubach; Paul G Richardson
Journal:  Clin J Am Soc Nephrol       Date:  2013-07-18       Impact factor: 8.237

3.  Kidney Transplantation in Patients With Active Multiple Myeloma: Case Reports.

Authors:  Erik Lawrence Lum; Neil Kogut; Thu Pham; Gabriel M Danovitch; Suphamai Bunnapradist
Journal:  Transplant Direct       Date:  2017-07-21

Review 4.  Multiple Myeloma and Renal Failure: Mechanisms, Diagnosis, and Management.

Authors:  Sumana Kundu; Surajkumar B Jha; Ana P Rivera; Gabriela V Flores Monar; Hamza Islam; Sri Madhurima Puttagunta; Rabia Islam; Ibrahim Sange
Journal:  Cureus       Date:  2022-02-25

5.  A therapeutic convection-enhanced macroencapsulation device for enhancing β cell viability and insulin secretion.

Authors:  Kisuk Yang; Eoin D O'Cearbhaill; Sophie S Liu; Angela Zhou; Girish D Chitnis; Allison E Hamilos; Jun Xu; Mohan K S Verma; Jaime A Giraldo; Yoshimasa Kudo; Eunjee A Lee; Yuhan Lee; Ramona Pop; Robert Langer; Douglas A Melton; Dale L Greiner; Jeffrey M Karp
Journal:  Proc Natl Acad Sci U S A       Date:  2021-09-14       Impact factor: 11.205

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.